DRG Epidemiology’s coverage of malignant melanoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
A range of oral and nonoral triptans (e.g., sumatriptan) are available for the acute treatment of migraine and are entrenched in medical practice. However, triptans have noted clinical shortcomings…
The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primarily effective in treating positive symptoms. However, in late 2019, the U.S…
More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to AED treatment. Opportunity in this arena has…
The asthma market in the EU5 is highly competitive. Many approved agents are available, including maintenance therapies—LABA/ICS FDCs (e.g., GSK’s Seretide and Relvar, AstraZeneca’s Symbicort…
Even though obesity is a significant public health concern that poses a substantial socioeconomic burden on the U.S. healthcare system, the reimbursement environment for antiobesity agents is very…
Nocturnal polyuria, a key contributing factor of nocturia in adults, is characterized by overproduction of urine at night. Changes in lifestyle and circadian rhythms, and conditions such as…
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics or targeted…